PPHLN1

PPHLN1 (Periphilin 1) is a core structural subunit of the HUSH (Human Silencing Hub) complex, which together with TASOR (FAM208A) and MPP8 (MPHOSPH8) directs H3K9me3-mediated epigenetic silencing of retrotransposons, unintegrated retroviral DNA, and proviruses (PMID:30297740, PMID:30487602). Recruitment to unintegrated retroviral DNA is mediated by the DNA-binding protein NP220, which brings the HUSH complex together with the SETDB1 methyltransferase and HDAC1/HDAC4 to target loci (PMID:30487602), and the relative stoichiometry of HUSH subunits tunes precise genomic localization for LINE-1 retrotransposon silencing (PMID:38313255). This silencing activity is antagonized by viral countermeasures: primate immunodeficiency virus Vpx/Vpr proteins associate with HUSH and direct PPHLN1 and other subunits to DCAF1/CUL4-mediated proteasomal degradation to de-repress proviruses (PMID:30297740), and the HUSH complex also restricts human adenovirus, which counteracts it via E1B-55K/E4orf6 [PMID:bio_10.1101_2025.02.10.637372]. Within mouse embryonic stem cells, PPHLN1 is dispensable for HUSH-mediated control of pluripotency exit, unlike MPP8 or TASOR (PMID:41291012). Independently of its silencing role, the PPHLN1 C-terminal region functions as a dimerization domain in the oncogenic FGFR2-PPHLN1 fusion protein found in intrahepatic cholangiocarcinoma, where transforming activity requires an active FGFR2 kinase domain, the PPHLN1-contributed dimerization domain, and membrane localization, driving MAPK/ERK, JAK/STAT3, and PI3K/AKT signaling (PMID:25608663, PMID:32854034).

1. 2015 Medium

   Established that PPHLN1 can act as an oncogenic fusion partner, framing a disease-relevant role distinct from any silencing function.

   Evidence RNA-/exome-sequencing identifying t(10;12) fusion plus in vitro transformation assays with FGFR2 inhibitor in intrahepatic cholangiocarcinoma

   PMID:25608663

   Open questions at the time

   • Which PPHLN1 region drives oncogenicity was not yet defined
   • No structural or reconstitution data on the fusion
   • Frequency and clinical scope of the fusion not addressed
2. 2018 High

   Defined PPHLN1 as one of three core HUSH subunits and showed its degradation is exploited by viruses to de-repress proviruses, establishing its central role in epigenetic silencing.

   Evidence Forward genetic screen, reciprocal Co-IP of Vpx with HUSH, knockdown of PPHLN1/FAM208A, and proteasome-dependent degradation Western blots

   PMID:30297740

   Open questions at the time

   • Molecular contribution of PPHLN1 to silencing versus TASOR/MPP8 not separated
   • Structural basis of HUSH assembly not resolved
3. 2018 High

   Showed how the HUSH complex is recruited to its targets, answering how PPHLN1-containing HUSH reaches unintegrated retroviral DNA.

   Evidence Genome-wide CRISPR-Cas9 screen and ChIP demonstrating NP220-dependent recruitment of HUSH, SETDB1, and HDAC1/4

   PMID:30487602

   Open questions at the time

   • Direct PPHLN1-NP220 contact not demonstrated
   • How recruitment is targeted at integrated proviruses versus unintegrated DNA unclear
4. 2021 Low

   Linked PPHLN1 to RNA-associated paraspeckle proteins, raising a possible role in RNA metabolism beyond chromatin silencing.

   Evidence Reciprocal Co-IP and proximity ligation assay showing PPHLN1 (and homolog BFARv3) interaction with NONO and SFPQ

   PMID:34175335

   Open questions at the time

   • Functional consequence of PPHLN1-NONO/SFPQ interaction not tested
   • Single lab, no orthogonal functional validation
   • Relationship to HUSH silencing not established
5. 2020 High

   Dissected the requirements of the FGFR2-PPHLN1 fusion, pinpointing the PPHLN1 moiety as the dimerization module needed for transformation.

   Evidence Soft agar/focus assays with kinase-dead, kinase-active, domain-deletion, and membrane-targeting constructs plus pathway inhibitor treatment in RIE-1 and NIH3T3 cells

   PMID:32854034

   Open questions at the time

   • Structural basis of PPHLN1-mediated dimerization not solved
   • Single lab; in vivo tumor relevance not tested
6. 2024 Medium

   Showed HUSH subunit stoichiometry controls precise genomic localization for LINE-1 silencing, refining how the complex achieves locus specificity.

   Evidence In silico structure prediction and MPP8-TASOR interface mutagenesis with LINE-1 silencing assays (preprint)

   PMID:38313255

   Open questions at the time

   • Computational structure not experimentally confirmed
   • PPHLN1-specific contribution to localization not isolated
   • Preprint, single lab
7. 2024 Medium

   Revealed crosstalk between HUSH and PRC1.6 in provirus silencing, broadening the chromatin context of HUSH function.

   Evidence Proximity labeling, genetic screen, and ChIP-seq with loss-of-function (preprint)

   PMID:39026796

   Open questions at the time

   • PPHLN1-specific role in PRC1.6 crosstalk not dissected
   • Preprint, single lab
8. 2024 Medium

   Implicated PPHLN1 alternative splicing in a stem cell program driving group 3 medulloblastoma, suggesting a tumor-relevant role distinct from the FGFR2 fusion.

   Evidence OTX2-splicing regulator interaction assays and in vivo tumor growth/survival assays with PPHLN1 splicing targeting

   PMID:39025928

   Open questions at the time

   • Mechanism of the PPHLN1 splice isoform's action not defined
   • Connection to HUSH silencing function not established
9. 2025 Medium

   Identified an endogenous retroviral microprotein partner of PPHLN1 required for HUSH target repression, hinting at a sensing/regulatory input.

   Evidence Co-IP of ERVK3-1 microprotein with PPHLN1 and loss-of-function with HUSH target gene expression readout

   PMID:40699144

   Open questions at the time

   • Direct mechanism by which ERVK3-1 modulates PPHLN1/HUSH unknown
   • Single study, single lab
10. 2025 Medium

    Demonstrated that PPHLN1 is functionally dispensable for HUSH-mediated pluripotency exit, distinguishing it from TASOR and MPP8 in this context.

    Evidence CRISPR knockout of PPHLN1 in mESCs with colony morphology and differentiation assays

    PMID:41291012

    Open questions at the time

    • Whether PPHLN1 is dispensable for retrotransposon silencing in the same system not addressed
    • Negative result for PPHLN1 specifically, single lab

• The structural basis of PPHLN1 incorporation into HUSH and its precise molecular contribution (versus TASOR/MPP8) to H3K9me3 deposition and locus targeting remain unresolved.
• No experimental structure of the PPHLN1-containing HUSH complex
• No defined biochemical activity assigned to PPHLN1 itself
• Reconciliation of dispensability in pluripotency exit with core-subunit status not established